100% agree Daniel E Spratt
Here's a popular #HIFU company's web posting...
Vs data they reference vs other published data... (note their ref has no RP nor RT data). Yes failure def'n different for RP vs RT but drives salvage = more toxicity
Maybe they need to hire new webmaster?

Christophe Hennequin, MD GETUG
☢️New GETUG-AFU 18 study reveals: Higher dose RT + long-term ADT boosts survival in high-risk prostate cancer without added long-term toxicity.
ASCO #GU24 OncoAlert UroToday.com OncoDaily Toni Choueiri, MD Emre Yekedüz Sophia Kamran, MD…

#GUretreat23 Ospedale San Raffaele Amazing number of ground breaking trials conducted under French GETUG & PEACE groups 👉Brilliant overview by ylt of GETUG/PEACE consortium 👇 Truly exemplifies academic research & opportunities for young investigators. Andrea Necchi OncoAlert

Ospedale San Raffaele #GURetreat23 ylt gives an amazing overview of the broad portfolio of GETUG GU clinical trials! Remarkable track record of practice changing trials at a fast pace!

Great presentation of NEMIO trial with ddMVAC + durva +/- treme for MIBC with pCR 48% & 18% Tx discontinued, excellent effort GETUG ESMO - Eur. Oncology #ESMO23 OncoAlert we are completing accrual in a trial with aMVAC/pembro Fred Hutchinson Cancer Center in histology subtypes Ali Khaki Sarah P. Psutka MD MS

Constance Thibault reported the GETUG of nemio trial (MVAC + durva +/- treme) in neoadj. Data that deserve confirmation. Ph3 testing chemo + IO ongoing

🟡 DARIUS phase II randomized trial 🟡
GETUG
Association Française d'Urologie - AFU

➡️➡️ Darolutamide vs ADT
In combination with RT for intermediate risk PCa

🙏Congrats to all investigators for the 15 pts included (N=62)
Supiot Stéphane Ulrike Schick Jonathan Khalifa David Pasquier Jonathan Khalifa

Journée #enseignement #recherche du GETUG #Cancer - 7eme édition 👍 Alexandre de La Taille Morgan Roupret Pignot Géraldine Laurence Albiges GETUG Association Française d'Urologie - AFU Association Française d'Urologie - AFU

Alberto Bossi Roubaud Guilhem Daniel E Spratt Kudos for impressive effort and team work to improve life of patients with advanced prostate cancer GETUG Pierre Blanchard, MD ylt Gustave Roussy #karimfizazi

Oncologists and urologists hand in hand 🤝 (or rather wheel in wheel 🚲) for a bike race in Chicago against prostate cancer! Echoing the Mont Ventoux event. #prostate #cancer Association Française d'Urologie - AFU GETUG Alexandre de La Taille Véronique Phé Benjamin Pradere Gaelle Fiard Nadia Abid

Overall survival from the vesper neoadjuvant trial from Getug and Association Française d'Urologie - AFU presented by C. Pfister And S.Culine at #ASCO23

PEACE-1:
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive #ProstateCancer (mCSPC):
☢️ Radiotherapy (RXT) of the prostate 74 Gy in 37 fractions (after docetaxel is completed) improve rPFS (median of 7.5 year) mOS not significant!
☢️minimal…

Vedang Murthy Priyamvada Maitre John Christodouleas Brian C. Baumann maneesh singh Prachi S. Mehta Similar trial in France.
🇫🇷GETUG AFU 30🇫🇷
Loco régional control is key.
Less than 50 % of the patients with pathological high risk features are eligible for #nivolumab .
So... Association Française d'Urologie - AFU Unicancer
GETUG Pignot Géraldine
⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️⬇️
clinicaltrials.gov/ct2/show/NCT03…

En allant sur le site du congrès, vous pouvez vous inscrire.
On attend aussi nombreux les précédents pays invités 🇧🇪🇧🇪🇮🇹🇮🇹 /
Et les sociétés savantes 🇫🇷🇫🇷 GETUG Association Française d'Urologie - AFU European Association of Urology (EAU) EAU Young Academics SFRO SFjRO AFUF AERIO 😷💉💉💉

Amar Kishan Piet Ost Sushil Memorial Sloan Kettering Cancer Center DARIUS is open. Radiotherapy +Daro vs Radiotherapy +ADT, 6 months.
🤞PSA-end end-point
Association Française d'Urologie - AFU GETUG Roubaud Guilhem
clinicaltrials.gov/ct2/show/NCT05…

2. BRCA2 mutation should not change treatment paradigm

Ccl:
- Unproven benefit of upfront surgery in very high risk/N1 pts
- Current evidence supports safety/efficacy of RT in BRCA2 mutation carriers
- Intensified systemic therapy key w/ RT as prognostic likely metastatic here

My arguments presented this morning #EAU23 for #radiotherapy + ADT/ARPA in patients with localized high risk PSMA-N1 BRCA mutated #prostatecancer .

Major thanks to all who provided input!

Two parts:
1. RT/ADT/ARPA is SOC

Lovely to have (almost) all the Gustave Roussy GU oncologists at this #GU23 in San Francisco with again excellent presentations Laurence Albiges Bernard-Tessier Natacha Naoun #ronanflippot #KarimFizazi #Bernardescudier